Treatment of psychosis: 30 years of progress

被引:46
作者
De Oliveira, I. R.
Juruena, M. F.
机构
[1] Fed Univ Salvador, Sch Med, Dept Neuropsychiat, Salvador, BA, Brazil
[2] Univ London, Univ London Kings Coll, Inst Psychiat, Dept Psychol Med, London SW3 6LX, England
关键词
atypical antipsychotic; pharmacology; psychosis; schizophrenia; treatment;
D O I
10.1111/j.1365-2710.2006.00784.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Thirty years ago, psychiatrists had only a few choices of old neuroleptics available to them, currently defined as conventional or typical antipsychotics, as a result schizophrenics had to suffer the severe extra pyramidal side effects. Nowadays, new treatments are more ambitious, aiming not only to improve psychotic symptoms, but also quality of life and social reinsertion. Our objective is to briefly but critically review the advances in the treatment of schizophrenia with antipsychotics in the past 30 years. We conclude that conventional antipsychotics still have a place when just the cost of treatment, a key factor in poor regions, is considered. The atypical antipsychotic drugs are a class of agents that have become the most widely used to treat a variety of psychoses because of their superiority with regard to extra pyramidal symptoms. We can envisage different therapeutic strategies in the future, each uniquely targeting a different dimension of schizophrenia, be it positive, negative, cognitive or affective symptoms.
引用
收藏
页码:523 / 534
页数:12
相关论文
共 82 条
[1]  
[Anonymous], 1980, DIAGN STAT MAN MENT
[2]  
[Anonymous], 1994, AM PSYCHIATR ASSOC
[3]   A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study [J].
Arato, M ;
O'Connor, R ;
Meltzer, HY .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2002, 17 (05) :207-215
[4]  
Ballas Christos, 2004, Expert Rev Neurother, V4, P179, DOI 10.1586/14737175.4.2.179
[5]   Olanzapine versus placebo and haloperidol - Acute phase results of the North American double-blind olanzapine trial [J].
Beasley, CM ;
Tollefson, G ;
Tran, P ;
Satterlee, W ;
Sanger, T ;
Hamilton, S ;
Fabre, L ;
Small, J ;
Ereshefsky, L ;
True, J ;
Nemeroff, C ;
Risch, SC ;
Perry, PJ ;
Potkin, SG ;
Borison, RL ;
James, S ;
Meltzer, HY ;
Iqbal, N ;
Fann, WE ;
Gewirtz, GR ;
Landbloom, R ;
RoyByrne, PP ;
Tuason, VB ;
Carman, JS ;
Stokes, PE ;
Williams, R ;
Ancill, RJ ;
MacEwan, GW ;
Gujavarty, KS ;
Jones, B ;
Lohr, JB .
NEUROPSYCHOPHARMACOLOGY, 1996, 14 (02) :111-123
[6]   Atypical antipsychotics: Part II - Adverse effects, drug interactions, and costs [J].
Brown, CS ;
Markowitz, JS ;
Moore, TR ;
Parker, NG .
ANNALS OF PHARMACOTHERAPY, 1999, 33 (02) :210-217
[7]   Efficacy of quetiapine for the treatment of schizophrenia: a combined analysis of three placebo-controlled trials [J].
Buckley, PF .
CURRENT MEDICAL RESEARCH AND OPINION, 2004, 20 (09) :1357-1363
[8]   Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors [J].
Burris, KD ;
Molski, TF ;
Xu, C ;
Ryan, E ;
Tottori, K ;
Kikuchi, T ;
Yocca, FD ;
Molinoff, PB .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2002, 302 (01) :381-389
[9]  
CARLSSON A, 1963, ACTA PHARMACOL TOX, V20, P140
[10]   RISPERIDONE IN THE TREATMENT OF NEGATIVE SYMPTOMS OF SCHIZOPHRENIA - A METAANALYSIS [J].
CARMAN, J ;
PEUSKENS, J ;
VANGENEUGDEN, A .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 1995, 10 (04) :207-213